This page shows the latest testosterone news and features for those working in and with pharma, biotech and healthcare.
In this study, Orgovyx achieved sustained testosterone suppression to castrate levels in 96.7% of patients from week five to week 48, in comparison to 88.8% for those receiving leuprolide ... It is designed to block the GnRH receptor, which in return
A response in the trial was defined as achieving and maintaining testosterone suppression at castration levels over the course of the 48-week study, and relugolix cleared the 90% rate required ... The data also showed that relugolix was also more
The new drug has a fairly benign safety profile, which is put down to the fact that it has minimal blood-brain barrier penetration and does not significantly increase testosterone levels
London. The work, delivered with support from digital agency Oi, provided a novel approach to restoring growth to Bayer’s established testosterone market leader Nebido.
cancer who have already had treatment to reduce testosterone and have had docetaxel chemotherapy.
Despite its effect on testosterone levels there was no accompanying increase in prostate specific antigen (PSA) levels. ... PSA levels are known to rise with testosterone replacement therapy (TRT) and there have been concerns TRT could activate or
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
Clarus Therapeutics pushed through with the launch of its testosterone replacement tablet, Jatenzo, despite the disruption caused by COVID-19.
Client:Bayer UK. Agency:Virgo Health and Oi Ltd. Campaign:Tackle TD. Timescale:N/A. Testosterone deficiency affects around one million British men, but symptoms like fatigue are often ignored, and ... One million British men are estimated to have
50 . Acerus (CA). Aytu (US). US license and commercialisation. Approved nasal testosterone for treatment of hypogonadism.
130. TesoRx Pharma/Aspen. Licence [C]. For TSX 002 an unmodified oral testosterone replacement.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.
methotrexate) for arthritis and advance the development of testosterone replacement therapy Vibex QS T.
Previously, he served as president and CEO of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US and he was co-founder
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...